Investing.com - Jazz Pharma (NASDAQ: JAZZ) reported first quarter EPS of $2.68, $1.50 worse than the analyst estimate of $4.18. Revenue for the quarter came in at $901.98M versus the consensus estimate of $953.95M.
Guidance
Jazz Pharma sees FY 2024 EPS of $18.15-$19.35 versus the analyst consensus of $18.95.
Jazz Pharma sees FY 2024 revenue of $4.00B-$4.20B versus the analyst consensus of $4.10B.
Jazz Pharma's stock price closed at $110.31. It is down -10.24% in the last 3 months and down -19.51% in the last 12 months.
Jazz Pharma saw 1 positive EPS revisions and 7 negative EPS revisions in the last 90 days. See Jazz Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Jazz Pharma's Financial Health score is "great performance".
Check out Jazz Pharma's recent earnings performance, and Jazz Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar